Oxford Drug Design uses AI and machine‑learning combined with deep expertise in tRNA synthetase biology to accelerate the discovery of novel therapeutics for cancer and other major diseases. Their platform integrates structural data, predictive modeling, and automated virtual screening to rapidly generate and optimize drug candidates with improved potency, selectivity, and safety, offering pharmaceutical and biotech partners a faster, more efficient path to targeted therapies.
Funding
$1.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PAFounders
Product
Problem
Developing new therapeutics against cancer and other major diseases is time‑consuming and costly, often hindered by limited understanding of target biology and inefficient screening methods.
Solution
Oxford Drug Design combines deep expertise in tRNA synthetase enzyme biology with AI and machine‑learning platforms to accelerate the identification and optimization of novel drug candidates. By integrating structural and functional data on tRNA synthetases with predictive algorithms, the company rapidly generates and validates compounds that modulate these targets. The AI‑driven workflow shortens the lead‑discovery cycle, improves hit quality, and enables iterative design of molecules with desired potency and safety profiles. This approach aims to deliver robust, targeted therapeutics for oncology and other high‑impact disease areas more efficiently than traditional discovery pipelines.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking accelerated discovery of targeted therapies for oncology and related disease programs.
Features
- Proprietary AI/ML models trained on tRNA synthetase structural and biochemical datasets to predict binding affinity and selectivity
- Automated virtual screening pipeline that prioritizes chemically diverse, drug‑like candidates for rapid synthesis
- Integrated in‑silico ADMET and toxicity prediction to filter out high‑risk compounds early in the process
- Iterative feedback loop linking experimental validation data back into the machine‑learning models for continuous improvement
- Focused library design targeting cancer‑relevant tRNA synthetase isoforms and other disease‑associated enzymes